drugset / Trial / NCT03172416

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis

NCT03172416 ↗

Phase 1 Unknown 21 enrolled National University Hospital, Singapore
NaSingle-groupOpen-labelTreatment

Summary

PIPAC is a procedure that involves the administration of intraperitoneal chemotherapy using an innovative concept that enhances the efficacy by taking advantage of the physical properties of gas and pressure. The chemotherapy drugs will be delivered in aerosolised form. This results in a superior distribution and depth of penetration of the drug. This research study serves to determine the safety profile and tolerability of PIPAC with oxaliplatin. It may offer a novel and effective option of treatment for patients with peritoneal carcinomatosis, who, at present have limited options involving the use of systemic chemotherapy and who suffer from poor life expectancy and poor quality of life. To date, most trials have used PIPAC cisplatin with doxorubicin, or oxaliplatin alone, and more studies are on-going globally. Intravenous (IV) nivolumab has been approved for the treatment of progressive gastric cancer after conventional chemotherapy. PIPAC in combination with nivolumab may have the potential to improve immune activation and response to immune checkpoint inhibition for patients with peritoneal disease. Hence we propose an amendment to our trial protocol for the addition of a second cohort (Cohort 2) to investigate the safety and tolerability of the combination of PIPAC oxaliplatin and IV nivolumab.

Timeline

Start
2017-04-12
Primary completion
2024-12-31
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 240 mg Intravenous
Subject Oxaliplatin Small molecule 45 mg/m2 Other
Subject Oxaliplatin Small molecule 60 mg/m2 Other
Subject Oxaliplatin Small molecule 90 mg/m2 Other
Subject Oxaliplatin Small molecule 120 mg/m2 Other
Subject Oxaliplatin Small molecule 150 mg/m2 Other